New therapies, new concerns: rituximab-associated lung injury

The indications for use of B-cell depleting therapy with the monoclonal antibody rituximab are progressively increasing in patients with renal disease. This includes patients with nephrotic syndrome and renal graft rejection. Late-onset pulmonary injury associated with rituximab therapy has been inc...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric nephrology (Berlin, West) West), 2010-06, Vol.25 (6), p.1001-1003
Main Author: Lands, Larry C.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents - adverse effects
Editorial Commentary
Humans
Lung diseases
Lung Injury - chemically induced
Lung Injury - pathology
Lung Injury - therapy
Medicine
Medicine & Public Health
Nephrology
Pediatrics
Rituximab
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The indications for use of B-cell depleting therapy with the monoclonal antibody rituximab are progressively increasing in patients with renal disease. This includes patients with nephrotic syndrome and renal graft rejection. Late-onset pulmonary injury associated with rituximab therapy has been increasingly recognized. While frequently reversible, it can be fatal. The spectrum of pulmonary disease associated with rituximab therapy, its investigation, and treatment are briefly reviewed.
ISSN:0931-041X
1432-198X
DOI:10.1007/s00467-010-1476-3